Genetic pathogenesis and targeted therapy in Chronic Myeloid Leukemia

21st century innovations in cutting-edge technologies have led to discovery of novel genetic, immunological and cell biological mechanisms underlying biology and parthenogenesis of different diseases including cancer. A special revolution has been made by this in diagnosis, prognosis and treatment of hematological malignancies specifically leukemias and lymphomas. Many molecular and immunological biomarkers have been discovered and utilized as drug targets to develop targeted molecular therapies in this regard. These efforts have specifically revolutionized clinically management of Chronic Myeloid Leukemia which has been transformed from a fatal disease to "almost-cured' cancer in first quarter of 21st century. Nevertheless, due to devil dynamic nature of cancer as a disease, there are still many challenges in CML prognosis and treatment. This book provides an account of molecular pathogenesis as well as current and prospective targeted therapies in CML. It also highlights some missing lessons and challenges in diagnosis, prognostic stratification, treatment monitoring, drug resistance and treatment-free remission of CML as well as major focus areas in CML treatment and research.